Halozyme Therapeutics Inc. (HALO)
Symbol Info
Listed Symbol HALO
Name Halozyme Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $151,862,000
Latest Fiscal EPS $-0.55
Price Info
21 Day Moving Average $15.8529
21 Day EMA $15.806810
50 Day Moving Average $16.1042
50 Day EMA $16.028790
200 Day EMA $16.333680
200 Day Moving Average 16.198650
52 Week High $18.10
52 Week Low $13.24
52 Week Change $-4.521100
Alpha 0.008755
Beta 1.7828
Standard Deviation 0.157651
R2 0.150980
Periods 60
Share Information
10 Day Average Volume 775,413
20 Day Average Volume 813,046
30 Day Average Volume 773,547
50 Day Average Volume 802,393
Outstanding Shares 146,310,920
Float Shares 135,269,441
Percent Float 92.45%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 434
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 13,675,410
Institute Holdings Percent -
Institute Sold Previous 3 Months 13,105,392
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 11,041,479
Price Change
7 Day Price Change $0.3399992
7 Day Percent Change 2.16%
21 Day Price Change $-0.3200016
21 Day Percent Change -1.95%
30 Day Price Change $-0.4700012
30 Day Percent Change -2.85%
Month To Date Price Change $0.5400
Month To Date Percent 3.48%
90 Day Price Change $-0.700001
90 Day Percent Change -4.18%
Quarter To Date $0.539999
Quarter To Date Percent 3.48%
180 Day Price Change $-0.68
180 Day Percent Change -4.06%
200 Day Price Change $0.349999
200 Day Percent Change 2.23%
Year To Date $1.419999
Year To Date Percent 9.71%
Profile
Description Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Details
Issue Type CS
Market Cap $2,348,290,266
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 146,310,920
CEO Helen I. Torley
Employees 281
Last Audit UE
Classification
CIK 0001159036
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 11388 Sorrento Valley Road
San Diego, CA 92121
Website http://www.halozyme.com
Facisimile +1 858 704-8311
Telephone +1 858 794-8889
Email ir@halozyme.com
Key Ratios
Profitability
EBIT Margin -15.7
EBITDA Margin -13.9
Pre-Tax Profit Margin -43.4
Profit Margin Cont -9.57
Gross Margin 93.00
Profit Margin TOT -9.57
Income Statements
Revenue $156,329,000
Revenue Per Share $1.0685
Revenue 3 Years $0.20
Revenue 5 Years $21.85
Valuation Measures
PE Ratio -
Enterprise Value $2,092,330,788
Price To Sales 15.021462
Price To Free Cash -106.3
PE High Last 5 Years -
Price To Book 9.9
Price To Cash Flow 24.6
PE Low Last 5 Years -
Price To Tangible Book 9.9
Financial Strength
Total Debt To Equity 0.4
Int Coverage -2.1
Current Ratio 2.9
Leverage Ratio 1.6
Quick Ratio 2.4
Long Term Debt To Capital 0.07
Assets
Receivables Turnover 2.2
Invoice Turnover 0.40
Assets Turnover 0.10
Management Effectiveness
Return Assets -9.59
Return On Equity -16.62
Return On Capital -7.47
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
HALO
Halozyme T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.